

17 September 2025

Rheumatology Drugs

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs?

Abatacept [Orencia]	288
Adalimumab [Humira]	243
Adalimumab Biosimilars	971
Apremilast [Otezla]	<5
Baricitinib [Olumiant]	28
Bimekizumab [Bimzelx]	28
Certolizumab [Cimzia]	139
Etanercept [Enbrel]	104
Etanercept Biosimilars	353
Filgotinib [Jyseleca]	<5
Golimumab [Simponi]	96
Guselkumab [Tremfya]	12
Infliximab [Remicade]	69
Infliximab Biosimilars - remsima	48
Ixekizumab [Taltz]	141
Risankizumab [Skyrizi]	<5
Rituximab [MabThera]	60
Rituximab Biosimilars	181
Sarilumab [Kevzara]	<5
Secukinumab [Cosentyx]	231
Tocilizumab [Ro Actemra]	171
Tocilizumab Biosimilars	<5
Tofacitinib [Xeljanz]	24
Upadacitinib [Rinvoq]	114
Ustekinumab [Stelara]	<5
Ustekinumab Biosimilar	5

Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis (PsA) ONLY in the last 3 months with the following drugs?

Rheumatology department are unable to breakdown the number of patients treated for Psoriatic Arthritis only in the last 3 months for the above drugs.

17 September 2025

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.